Популярная добавка для суставов вызывает умственную неполноценность.

Overview

The video argues against taking glucosamine (a popular joint supplement), claiming it may increase the risk of cognitive decline and faster progression of Alzheimer’s disease.

Main claims and reasoning

• Low or negligible joint benefit: The speaker says glucosamine produces only a very small pain reduction (described as a few points on a 100-point pain scale) and does not “restore” cartilage—so the benefit is close to zero.

• Biological mechanism linking glucosamine to Alzheimer’s: The video describes a study suggesting Alzheimer’s is associated with increased glycosylation (adding sugar chains to proteins). The speaker explains that excessive sugar tagging can change protein behavior and disrupt normal brain function.

• Glucosamine as a “building material” for this process: According to the video, glucosamine can feed into the biochemical pathway that increases those sugar tags. In people already vulnerable to neurodegeneration, glucosamine could potentially intensify harmful protein modifications.

Evidence discussed

Animal experiments (Alzheimer’s models in mice)

• Researchers observed increased sugar chains in brain regions tied to memory (e.g., cortex and hippocampus).
• Reducing glycosylation-related pathway activity improved memory/behavior in mice.
• Giving glucosamine to Alzheimer’s-model animals worsened memory, described as similar to increasing glycosylation burden.
• The speaker notes this cognitive harm was not seen in “healthy flies,” suggesting vulnerability may depend on disease state rather than being universal.

Human observational data (University of Florida Health database)

• The video cites analysis of 24,481 Alzheimer’s/dementia-related patients and 41,884 with mild cognitive impairment (MCI).
• Glucosamine use was recorded in about 8% of patients.
• Over roughly 5 years, users with dementia had an approximately 25% increased risk of death.
• In MCI patients, transition to dementia was reportedly about 25% higher in glucosamine users.
• The video emphasizes a key limitation: this is observational data, not a randomized placebo-controlled trial.

Practical conclusion presented

• The speaker recommends avoiding glucosamine after about 55–60 years, especially if there is any forgetfulness, MCI, or diagnosed dementia—framing glucosamine as avoidable risk with minimal payoff.
• The video argues that pain relief sensations don’t prove glucosamine is truly treating joints, since pain fluctuates and effects may be confounded by factors like expectations, activity, weight, and medications.
• It also warns that glucosamine is sometimes included indirectly in “joint support” blends (e.g., glucosamine + chondroitin/MSM/collagen/hyaluronic acid), so people may not realize they are taking it.

Key takeaway

The video frames glucosamine as a “just in case” supplement that may no longer be risk-free: near-zero joint pain benefit (as presented) versus potentially meaningful increased risk of cognitive worsening in vulnerable populations.

Presenters / contributors

• No specific individual presenters are named in the subtitles (only “Hello friends” and references to researchers/scientists).